Thrombolex, Inc.

Our goal is to create a continuous stream of new products based on the original BASHIR™ platform technology, which will improve the treatment outcomes for patients suffering from acute VTE conditions, by creating innovative endovascular catheters for use in the treatment of patients with acute venous thromboembolic (VTE) conditions. Our vision for success is to orchestrate the medical profession’s identified unmet needs with our unique product development capabilities.

Historically, the Thrombolex leadership team led the successful creation of multiple novel medical devices and start-up companies. Most notable is the generations of specialty stents, which led to a transformational change in the endovascular treatment of obstructive lesions in the coronary, iliac, renal and carotid arteries. Now, this team has focused on solutions to the under-recognized and under-treated problems in the venous circulation, especially pulmonary embolism (PE) and deep vein thrombosis (DVT). This has resulted in the creation of BASHIR™ Endovascular Catheters, which provide a unique platform technology for use in the treatment of venous thromboembolic (VTE) conditions.

Company’s Keywords: